CSL initiated with an Overweight at Morgan Stanley [Yahoo! Finance]
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $74.00 to $68.00. They now have a "buy" rating on the stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) was given a new $48.00 price target on by analysts at BTIG Research.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its price target lowered by analysts at HC Wainwright from $63.00 to $60.00. They now have a "buy" rating on the stock.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.